UTHR (United Therapeutics) Owner Earnings per Share (TTM): 21.01 (As of Mar. 2026) — 34% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UTHR United Therapeutics Corp UTHR
88 GF Score
Price $527.47
GF Value $387.20
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is United Therapeutics Owner Earnings per Share (TTM)?

United Therapeutics UTHR -0.07% 88 Owner Earnings per Share (TTM) is 21.01 as of Mar. 2026, which is 34% above its 10-year median of 15.64. GuruFocus rates UTHR with a GF Scoreâ„¢ of 88/100 and a GF Valueâ„¢ of $387.20 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 474 Drug Manufacturers companies, United Therapeutics ranks worse than 52.11% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

United Therapeutics's Owner Earnings per Share (TTM) ended in Mar. 2026 was $21.01. It's Price-to-Owner-Earnings ratio for today is 25.11.


The historical rank and industry rank for United Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:

UTHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.97   Med: 15.64   Max: 40.84
Current: 25.09


During the past 13 years, the highest Price-to-Owner-Earnings ratio of United Therapeutics was 40.84. The lowest was 5.97. And the median was 15.64.


UTHR's Price-to-Owner-Earnings is ranked worse than
52.11% of 474 companies
in the Drug Manufacturers industry
Industry Median: 23.54 vs UTHR: 25.09

United Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $5.82. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $27.09. It's PE Ratio (TTM) ratio for today is 19.47.

United Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $5.82. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $27.46. It's PE Ratio without NRI ratio for today is 19.21.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


United Therapeutics Owner Earnings per Share (TTM) Related Terms


United Therapeutics Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Owner Earnings per Share (TTM) Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.35 10.84 18.01 23.56 23.13

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.57 23.28 26.73 23.13 21.01

UTHR vs VTRS, NBIX, ZTS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Price-to-Owner-Earnings falls into.


UTHR
88GF Score
United Therapeutics Corp UTHR
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

United Therapeutics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 1,287
Depreciation, Depletion and Amortization 88
Change In Deferred Tax 26
5Y Average of Maintenance Capital Expenditure 238
Change In Working Capital -172
Shares Outstanding (Diluted Average) 47

1. Start with "Net Income" from income statement. United Therapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was $1,287 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. United Therapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was $88 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. United Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was $26 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $238 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

United Therapeutics's 5-Year Average Maintenance Capital Expenditure = $238 Mil

5. "Change In Working Capital" is from cashflow statement. United Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was $-172 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. United Therapeutics's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 47.200 Mil.

United Therapeutics's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 1287.4 +88.4+25.9
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-237.72232798897+-172.1)/47.200
=21.01

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=527.47/21.01
=25.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 21.01 mean?
United Therapeutics (UTHR) has a Owner Earnings per Share (TTM) of 21.01 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on United Therapeutics. This is 34% above median its historical median of 15.64. Over the past decade, United Therapeutics' Owner Earnings per Share (TTM) has ranged from 5.97 to 40.84. According to the industry distribution chart, United Therapeutics ranks #247 out of 474 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is United Therapeutics' Owner Earnings per Share (TTM) too high?
United Therapeutics' current Owner Earnings per Share (TTM) of 21.01 is 34% above median its 10-year median of 15.64. Over the past 10 years, this metric has ranged from a low of 5.97 to a high of 40.84. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.54. United Therapeutics' value of 21.01 is 10.7% below this industry median. Based on the distribution chart, United Therapeutics ranks #247 out of 474 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, United Therapeutics has a GF Scoreâ„¢ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Owner Earnings per Share (TTM) compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #247 out of 474 companies for Owner Earnings per Share (TTM). This places United Therapeutics in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.54. United Therapeutics' value of 21.01 is 10.7% below this benchmark. Historically, United Therapeutics' own Owner Earnings per Share (TTM) has ranged from 5.97 to 40.84 over the past decade. While the company's 10-year median is 15.64 vs. the industry median of 23.54, United Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.54, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current Owner Earnings per Share (TTM) of 21.01 is 10.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on United Therapeutics. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Owner Earnings per Share (TTM) is 21.01, which is 34% above median its own 10-year median of 15.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $387.20, compared to a current price of $527.47 — trading 36.2% above its estimated fair value. The current Owner Earnings per Share (TTM) is 21.01, which is 34% above median its 10-year median of 15.64 and 10.7% below the Drug Manufacturers industry median of 23.54. United Therapeutics' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Owner Earnings per Share (TTM) is 21.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $527.47 is trading 36.2% above its estimated GF Value™ of $387.20. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Owner Earnings per Share (TTM): 21.01 (34% above median its 10-year median of 15.64)
  • GF Value™: $387.20 vs. price of $527.47 (36.2% above fair value)
  • GF Score™: 88/100 with 3 warning signs
  • Industry Position: 10.7% below the Drug Manufacturers median (#247 of 474)

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$527.47
Price
$387.20
GF Value